PlaqueTec is a pioneering brand dedicated to revolutionizing personalized medicine for Coronary Artery Disease (CAD). Our ultimate goal is to enable clinicians to accurately assess patients' risk of future events and provide individualized treatment. At the core of our innovative approach is our Liquid Biopsy System (LBS), a groundbreaking technology that allows for the identification and collection of biomarker samples from vulnerable plaque within coronary arteries.

This provides crucial insights into vascular function, inflammation, and coronary plaque progression. Guided by leading experts in cardiovascular medicine, PlaqueTec is mapping the biological processes of CAD in unprecedented detail. We are actively building a comprehensive database of identified biomarkers, which will be instrumental in translational research, personalized therapies, and evaluating the performance of both existing and new drugs targeting the inflammatory processes underlying CAD progression.

Join us in transforming the prevention, diagnosis, and treatment of CAD, the leading cause of death worldwide. Contact PlaqueTec for research and partnering opportunities and witness the transformative power of the PlaqueTec Liquid Biopsy System™ in action